Navigation Links
First antibiotic stewardship probed in the Journal of the Pediatric Infectious Diseases Society
Date:8/9/2012

ARLINGTON, VA, August 9, 2012The Journal of the Pediatric Infectious Diseases Society (JPIDS) today released the largest and most rigorous evaluation to date of the impact on reducing the days of antibiotic therapy in a children's hospital using a prospective-audit-with-feedback antibiotic stewardship program (ASP). The study utilized a control group of the 25-member children's hospitals of the Child Health Corporation of America. A companion article describes how the ASP was created within this 317-bed tertiary care children's hospital and clinicians' attitudes toward itthe first published account of such a pediatric program.

Up to 35% of inpatient antibiotic prescriptions are either unnecessary or inappropriate. The Infectious Diseases Society of America's (IDSA) 2007 guideline on the implementation of hospital ASPs described two core stewardship strategies to curb the rise of drug-resistant microbes: prospective-audit-with-feedback, and preauthorization. IDSA said that research would be needed to determine whether these strategies would be effective in pediatrics.

In this more-than-33-month study of 8,765 patients, Newland et al, observed a significant decrease in antibiotic usageranging from a 37% decrease in the early months, to 13% at the end of the observation. In particular, the study showed up to a 19% monthly reduction in broad-spectrum antibiotics, which the Centers for Disease Control and Prevention have recommended avoiding in order to prevent resistance in hospitalized children.

In the companion article, Stach et al, describe the five-part process they used to create their ASP, including: forming a multi-disciplinary team; determining the type of program (prospective-audit-with-feedback) and which antimicrobials to monitor; deciding which mechanism to use in identifying patients (a report was created in the hospital's EMR system); developing and implementing an evaluation process; and, communicating the goals and logistics of the ASP to the hospital's affected clinicians.

The authors surveyed 365 clinicians; the 56% who responded had a positive view of the ASP. The overwhelming majority agreed that the ASP had improved the use (83%) of antibiotics, decreased their inappropriate use (84%), and improved the quality of patient care (82%). An ASP goal was to provide education to those affected by the program; 90% said it did and 66% agreed it led to practice changes. Of negative feelings, only 6% felt the ASP interfered with clinical decision-making and 5% thought the ASP's recommendations were threatening.


'/>"/>
Contact: Jodie Klein
jodieklein@kleinonpoint.com
703-528-3333
Pediatric Infectious Diseases Society
Source:Eurekalert

Related biology news :

1. Kessler Foundation implements Ekso Bionics first commercial robotic exoskeleton
2. Research reveals first evidence of hunting by prehistoric Ohioans
3. First model of how buds grow into leaves
4. American College of Rheumatology releases first classification criteria for polymyalagia rheumatica
5. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
6. First complete full genetic map of promising energy crop
7. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
8. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
9. New technology tracks sparrow migration for first time from California to Alaska
10. First mass extinction linked to marine anoxia
11. Scientists complete first-ever emperor penguin count from space
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... ... , ... The Society for Immunotherapy of Cancer (SITC) strongly opposes the proposed ... fiscal year 2018 budget request. , This proposal calls for a ... roughly 20% of its total budget. If applied proportionally across NIH, funding for the ...
(Date:3/22/2017)... , March 22, 2017  RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... Chief Business Officer, will present at the 5th ... will provide a platform to present to and ... leading pharmaceutical and biotech companies as well as ...
(Date:3/20/2017)... ... March 20, 2017 , ... ... and biotech companies, recently announced it will debut a brand new pressure vessel, ... The intelliVessel is controlled by a touch screen panel and features other revolutionary ...
(Date:3/20/2017)... , ... March 20, 2017 , ... The fourth annual ... while innovating to make an extraordinary impact on peoples’ lives, launches today. Sponsored by ... challenge every 5 weeks and awards thousands in cash prizes to engineers, inventors and ...
Breaking Biology Technology: